Cargando…

The hard road to ranking the clinical benefit of antineoplastic agents: ESMO Award 2016 presentation

Detalles Bibliográficos
Autor principal:	Sobrero, Alberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	ESMO Open 2017
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519818/ https://www.ncbi.nlm.nih.gov/pubmed/28761732 http://dx.doi.org/10.1136/esmoopen-2017-000157

Ejemplares similares

Applying the ESMO-Magnitude of Clinical Benefit Scale in real life
por: Ciardiello, Fortunato, et al.
Publicado: (2016)

ESMO Copenhagen 2016: a lung cancer ‘grand cru’
por: Douillard, Jean-Yves
Publicado: (2017)

ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers
por: Cherny, N I, et al.
Publicado: (2016)

ESMO/ASCO recommendations for a Global Curriculum (GC) in medical oncology—edition 2016
por: Dittrich, C., et al.
Publicado: (2016)

My personal highlights of ESMO 2016
por: Dediu, M., et al.
Publicado: (2017)

Design and Synthesis of Organic Molecules as Antineoplastic Agents
por: Boga, Carla, et al.
Publicado: (2020)

Highlights for ESMO 40: celebration review for lifetime achievement awards
por: Saijo, Nagahiro
Publicado: (2016)

Detailed statistical assessment of the characteristics of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) threshold rules
por: Dafni, Urania, et al.
Publicado: (2017)

ESMO Women for Oncology 2016: a very personal tale of my professional life in Asia
por: Thongprasert, Sumitra
Publicado: (2017)

ESMO-Magnitude of Clinical Benefit Scale (MCBS) group
por: Amaral, Teresa
Publicado: (2019)

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring
por: Gyawali, B., et al.
Publicado: (2021)

Editorial: NAR Awards 2016
Publicado: (2016)

Implementation of the ESMO-Magnitude of Clinical Benefit Scale: real world example from the 2022 Israeli National Reimbursement Process
por: Wolf, I., et al.
Publicado: (2022)

PB2707: ESMO-MAGNITUDE OF CLINICAL BENEFIT SCALE FOR HAEMATOLOGICAL MALIGNANCIES (ESMO-MCBS:H) VERSION 1.0
por: Kiesewetter, Barbara, et al.
Publicado: (2023)

ESMO gave me a chance to help make a difference: a personal reflection on the occasion of receiving the 2015 ESMO Award
por: Cherny, Nathan I
Publicado: (2016)

Challenge of implementing clinical practice guidelines. Getting ESMO’s guidelines even closer to the bedside: introducing the ESMO Practising Oncologists’ checklists and knowledge and practice questions
por: Rauh, Stefan, et al.
Publicado: (2018)

AIOM chooses ESMO Open—Cancer Horizons as its official journal: a warm welcome from ESMO Open
por: Zielinski, Christoph C, et al.
Publicado: (2016)

Editor’s choice 2019: Oxidative stress and antineoplastic agents
por: Ghallab, Ahmed
Publicado: (2020)

ESMO International Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in countries outside of Europe
por: Cherny, N I, et al.
Publicado: (2017)

EHA Endorsement of ESMO Clinical Practice Guidelines for Marginal Zone Lymphomas
por: Ladetto, Marco, et al.
Publicado: (2020)

CSCO joins ESMO Open—Cancer Horizons
por: Zielinski, Christoph C, et al.
Publicado: (2016)

ESMO Open—Cancer Horizons and the future of oncology
por: Zielinski, Christoph C
Publicado: (2016)

ESMO pays tribute to Professor José Baselga
por: Peters, S., et al.
Publicado: (2021)

Announcement of the 2016 Polymers Young Investigator Award
por: Böker, Alexander
Publicado: (2016)

EHA evaluation of the ESMO—Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies
por: Kiesewetter, Barbara, et al.
Publicado: (2020)

Evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for adjuvant radiotherapy in breast cancer
por: Sapir, E., et al.
Publicado: (2023)

2016 ISCB Overton Prize awarded to Debora Marks
por: Fogg, Christiana N., et al.
Publicado: (2016)

Announcement of the Diagnostics 2016 Junior Scientists Travel Award
Publicado: (2016)

Announcing the 2016 Pharmaceuticals Travel Award for Young Investigators
por: Vanden Eynde, Jean Jacques
Publicado: (2016)

Clinical benefit of systemic therapies for recurrent ovarian cancer—ESMO-MCBS scores
por: Broekman, K.E., et al.
Publicado: (2021)

EHA Endorsement of ESMO Clinical Practice Guidelines for Newly Diagnosed and Relapsed Follicular Lymphoma
por: Ladetto, Marco, et al.
Publicado: (2021)

ESMO Clinical Practice Guidelines: adapting and adopting new approaches for development, implementation and audit
por: Pentheroudakis, G., et al.
Publicado: (2022)

ESMO and WHO: 14 years of working in partnership on cancer control
por: Ullrich, Andreas, et al.
Publicado: (2016)

Introducing pro and con discussions in ESMO Open—Cancer Horizons
por: Zielinski, C., et al.
Publicado: (2022)

Endocrine Toxicities of Antineoplastic Therapy
por: Puliani, Giulia, et al.
Publicado: (2021)

The 2016 Ming K Jeang Award for Excellence in Cell & Bioscience
por: Shi, Yun-Bo
Publicado: (2017)

International Journal of Molecular Sciences 2016 Best Paper Award
Publicado: (2016)

EHA Endorsement of ESMO Clinical Practice Guidelines for Newly Diagnosed and Relapsed Mantle Cell Lymphoma
por: Linton, Kim, et al.
Publicado: (2020)

EHA Endorsement of ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up for Waldenström’s Macroglobulinemia
por: Staber, Philipp B., et al.
Publicado: (2021)

EHA Endorsement of ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up for Myelodysplastic Syndromes
por: van de Loosdrecht, Arjan A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2hept5d9uiuuejjimasljor39k